1-[4-(4-甲基哌嗪)苯基]-1-苯乙酮 | 26586-55-0

• 物质功能分类: 医药中间体 - 杂环化合物 - 哌嗪类化合物
• 分子结构分类: 有机化合物 - 有机氧化合物
• 中文名称: 1-[4-(4-甲基哌嗪)苯基]-1-苯乙酮
• 中文别名: 4-(4-甲基哌嗪基)苯乙酮；4-(4-甲基哌嗪子基)苯乙酮
• 英文名称: 1-[4-(4-methylpiperazin-1-yl)phenyl]ethanone
• 英文别名: 1-(4-(4-methylpiperazin-1-yl)phenyl)ethan-1-one；4-(4-Methyl-piperazino)-acetophenon；p-(4-methyl-1-piperazinyl)acetophenone；Acetophenone, 4'-(4-methyl-1-piperazinyl)-
• CAS: 26586-55-0
• 化学式: C₁₃H₁₈N₂O
• mdl: MFCD00023297
• 分子量: 218.299
• InChiKey: IRIZGAMYKHTLKS-UHFFFAOYSA-N

物化性质

• 熔点：
  96-100 °C
• 沸点：
  358.99°C (rough estimate)
• 密度：
  1.0346 (rough estimate)
• 稳定性/保质期：
  遵照规定使用和储存，则不会分解。

计算性质

• 辛醇/水分配系数(LogP)：
  1.5
• 重原子数：
  16
• 可旋转键数：
  2
• 环数：
  2.0
• sp3杂化的碳原子比例：
  0.461
• 拓扑面积：
  23.6
• 氢给体数：
  0
• 氢受体数：
  3

安全信息

• 危险等级：
  IRRITANT
• 安全说明：
  S24/25
• 储存条件：
  存放在阴凉干燥处即可。

SDS

Name:	4-(4-Methylpiperazino)-acetophenone 98% Material Safety Data Sheet
Synonym:	Non
CAS:	26586-55-0

Section 1 - Chemical Product MSDS Name:4-(4-Methylpiperazino)-acetophenone 98% Material Safety Data Sheet
Synonym:Non

---

Section 2 - COMPOSITION, INFORMATION ON INGREDIENTS

CAS#	Chemical Name	content	EINECS#
26586-55-0	4-(4-Methylpiperazino)-acetophenone	98.0	247-827-5

Hazard Symbols: None Listed.
Risk Phrases: None Listed.

---

Section 3 - HAZARDS IDENTIFICATION
EMERGENCY OVERVIEW
The toxicological properties of this material have not been fully investigated.
Potential Health Effects
Eye:
No information regarding eye irritation and other potential effects was found.
Skin:
No information regarding skin irritation and other potential effects was found.
Ingestion:
The toxicological properties of this substance have not been fully investigated.
Inhalation:
The toxicological properties of this substance have not been fully investigated.
Chronic:
No information found.

---

Section 4 - FIRST AID MEASURES
Eyes: Flush eyes with plenty of water for at least 15 minutes, occasionally lifting the upper and lower eyelids. Get medical aid immediately.
Skin:
Get medical aid. Flush skin with plenty of water for at least 15 minutes while removing contaminated clothing and shoes. Wash clothing before reuse.
Ingestion:
If victim is conscious and alert, give 2-4 cupfuls of milk or water.
Never give anything by mouth to an unconscious person. Get medical aid immediately.
Inhalation:
Get medical aid immediately. Remove from exposure and move to fresh air immediately. If not breathing, give artificial respiration. If breathing is difficult, give oxygen.
Notes to Physician:
Antidote: None reported.

---

Section 5 - FIRE FIGHTING MEASURES
General Information:
As in any fire, wear a self-contained breathing apparatus in pressure-demand, MSHA/NIOSH (approved or equivalent), and full protective gear.
Extinguishing Media:
Use foam, dry chemical, or carbon dioxide.

---

Section 6 - ACCIDENTAL RELEASE MEASURES
General Information: Use proper personal protective equipment as indicated in Section 8.
Spills/Leaks:
Absorb spill with inert material (e.g. vermiculite, sand or earth), then place in suitable container. Avoid generating dusty conditions.
Provide ventilation.

---

Section 7 - HANDLING and STORAGE
Handling:
Wash thoroughly after handling. Use with adequate ventilation.
Minimize dust generation and accumulation. Avoid contact with eyes, skin, and clothing. Keep container tightly closed. Avoid ingestion and inhalation. Use only in a chemical fume hood.
Storage:
Store in a tightly closed container. Store in a cool, dry, well-ventilated area away from incompatible substances.

---

Section 8 - EXPOSURE CONTROLS, PERSONAL PROTECTION
Engineering Controls:
Facilities storing or utilizing this material should be equipped with an eyewash facility and a safety shower. Use adequate general or local explosion-proof ventilation to keep airborne levels to acceptable levels.
Exposure Limits CAS# 26586-55-0: Personal Protective Equipment Eyes: Wear appropriate protective eyeglasses or chemical safety goggles as described by OSHA's eye and face protection regulations in 29 CFR 1910.133 or European Standard EN166.
Skin:
Wear appropriate protective gloves to prevent skin exposure.
Clothing:
Wear appropriate protective clothing to prevent skin exposure.
Respirators:
Follow the OSHA respirator regulations found in 29 CFR 1910.134 or European Standard EN 149. Use a NIOSH/MSHA or European Standard EN 149 approved respirator if exposure limits are exceeded or if irritation or other symptoms are experienced.

---

Section 9 - PHYSICAL AND CHEMICAL PROPERTIES

Physical State: Solid
Color: Not available.
Odor: Not available.
pH: Not available.
Vapor Pressure: Not available.
Viscosity: Not available.
Boiling Point: Not available.
Freezing/Melting Point: 98 deg C
Autoignition Temperature: Not available.
Flash Point: Not available.
Explosion Limits, lower: N/A
Explosion Limits, upper: N/A
Decomposition Temperature:
Solubility in water:
Specific Gravity/Density:
Molecular Formula: C13H18N2O
Molecular Weight: 218.30

---

Section 10 - STABILITY AND REACTIVITY
Chemical Stability:
Has not been fully evaluated.
Conditions to Avoid:
Dust generation.
Incompatibilities with Other Materials:
Strong oxidizing agents Hazardous Decomposition Products:
Nitrogen oxides, carbon monoxide, carbon dioxide.
Hazardous Polymerization: Has not been reported.

---

Section 11 - TOXICOLOGICAL INFORMATION
RTECS#:
CAS# 26586-55-0: AM9472500 LD50/LC50:
Not available.
Carcinogenicity:
4-(4-Methylpiperazino)-acetophenone - Not listed by ACGIH, IARC, or NTP.
Other:
See actual entry in RTECS for complete information.

---

Section 12 - ECOLOGICAL INFORMATION
Other No information available.

---

Section 13 - DISPOSAL CONSIDERATIONS
Dispose of in a manner consistent with federal, state, and local regulations.

---

Section 14 - TRANSPORT INFORMATION

IATA
Not regulated as a hazardous material.
IMO
Not regulated as a hazardous material.
RID/ADR
Not regulated as a hazardous material.

---

Section 15 - REGULATORY INFORMATION

European/International Regulations
European Labeling in Accordance with EC Directives
Hazard Symbols: Not available.
Risk Phrases:
Safety Phrases:
S 24/25 Avoid contact with skin and eyes.
WGK (Water Danger/Protection)
CAS# 26586-55-0: No information available.
Canada
None of the chemicals in this product are listed on the DSL/NDSL list.
CAS# 26586-55-0 is not listed on Canada's Ingredient Disclosure List.
US FEDERAL
TSCA
CAS# 26586-55-0 is not listed on the TSCA inventory.
It is for research and development use only.

---

SECTION 16 - ADDITIONAL INFORMATION
N/A

反应信息

• 作为反应物：
  描述：

  1-[4-(4-甲基哌嗪)苯基]-1-苯乙酮 在 吗啉 、 氯化亚砜 、 对甲苯磺酸 、 sulfur 作用下， 以 水 为溶剂， 反应 4.0h， 生成 methyl 2-[4-(4-methylpiperazin-1-yl)phenyl]acetate
  参考文献：
  名称：

  Inhibitors of protein kinases

  摘要：

  通用式(I)的化合物： 其中R1、R2、R3、Ra、A、B和x的定义如本文所述，是特定于细胞周期蛋白激酶家族和/或糖原合成酶激酶3家族的抑制剂，并且在预防和/或治疗任何类型的疼痛、炎症性疾病、癌症、免疫性疾病、增殖性疾病、传染病、心血管疾病、代谢性疾病、肾脏疾病、神经和神经精神疾病以及神经退行性疾病方面具有用处。

  公开号：

  US20110224225A1
• 作为产物：
  描述：

  4-乙酰基-苯甲酰胺 以 1,2-二氯乙烷 、 乙腈 为溶剂， 反应 6.0h， 生成 1-[4-(4-甲基哌嗪)苯基]-1-苯乙酮
  参考文献：
  名称：

  一种新颖且不寻常的苯环与各种胺之间形成C[sbnd]N键的方法

  摘要：

  开发了一种无需金属催化形成 CN 键的新方法。 4-乙酰基苯甲酰异氰酸酯与各种胺通过温和的方法反应形成CN键。该反应易于放大，并提供了具有良好至优异产率的相应产物，并且耐受多种官能团。

  DOI：

  10.1016/j.tetlet.2021.153355
• 作为试剂：
  描述：

  N-甲基哌嗪 、 4-氟苯乙酮 在 水 、 sodium hydroxide 、 1-[4-(4-甲基哌嗪)苯基]-1-苯乙酮 作用下， 以 二甲基亚砜 为溶剂， 反应 16.0h， 生成 1-[4-(4-甲基哌嗪)苯基]-1-苯乙酮
  参考文献：
  名称：

  Substituted-1,2-dihydro-2-oxonicotinyl-cephalosporins

  摘要：

  本发明提供了新型有机酰胺化合物，其为N-[6-[(取代氨基)苯基]1,2-二氢-2-氧基烟酰基]青霉素和头孢菌素类型化合物，具有广谱抗菌作用，其方法为(a)将适当的青霉素或头孢菌素的游离氨基酸或其酸盐或硅烷衍生物与相应的N-6-[(取代氨基)苯基]-1,2-二氢-2-氧基烟酸的反应性衍生物反应，或者(b)将游离氨基酸6-氨基青霉烷酸、7-氨基头孢烷酸、7-氨基-3-甲基头孢-3-乙烯-4-羧酸或相关化合物或其酸盐或硅烷衍生物与相应的D-N-[6-[(取代氨基)苯基]-1,2-二氢-2-氧基烟酰基]-2-取代甘氨酸的反应性衍生物反应。本发明还公开了含有所述化合物的制药组合物以及使用所述组合物治疗感染的方法。

  公开号：

  US04053470A1

文献信息

• [EN] ARYLPYRAZOLES AND ARYLISOXAZOLES AND THEIR USE AS PKD MODULATORS<br/>[FR] ARYLPYRAZOLES ET ARYLISOXAZOLES ET LEUR UTILISATION EN TANT QUE MODULATEURS DE LA PROTÉINE KINASE C (PKD)
  申请人：NOVARTIS AG

  公开号：WO2011009484A1

  公开（公告）日：2011-01-27

  The present invention provides novel organic compounds of formula (I) or (Ia): which may be inhibitors of a selective subset of kinases belonging to the AGC or calmodulin kinase family, such as for example PKD-1/2/3, inhibitors of histone deacetylase (HDAC) phosphorylation, or inhibitors of other kinases. The selectivity of which would depend on the structural variation thereof, and for treatment of a disorder or disease mediated by those selected AGC or calmodulin family kinases. These organic compounds can be used to treat various PKD associated states such as heart failure, colorectal cancer, regulation of cell growth, autoimmune disorders, or hyperproliferative skin disorders.

  本发明提供了化学式(I)或(Ia)的新型有机化合物：这些化合物可能是AGC或钙调素激酶家族中的一部分激酶的抑制剂，例如PKD-1/2/3，组蛋白去乙酰化酶（HDAC）磷酸化的抑制剂，或其他激酶的抑制剂。其选择性取决于其结构变化，用于治疗由这些选定的AGC或钙调素家族激酶介导的疾病或疾病。这些有机化合物可用于治疗各种PKD相关状态，如心力衰竭、结直肠癌、细胞生长调节、自身免疫性疾病或过度增生性皮肤疾病。
• [EN] PYRIMIDINONE DERIVATIVES AND USES THEREOF TO NEUTRALIZE THE BIOLOGICAL ACTIVITY OF CHEMOKINES<br/>[FR] DÉRIVÉS DE PYRIMIDINONE ET LEURS UTILISATIONS POUR NEUTRALISER L'ACTIVITÉ BIOLOGIQUE DES CHIMIOKINES
  申请人：CENTRE NATIONAL DE LA RECHERCHE SCIENT - CNRS -

  公开号：WO2018011376A1

  公开（公告）日：2018-01-18

  A subject of the present invention is a compound having the general formula (I) a pharmaceutically acceptable salt thereof or a tautomeric form thereof, wherein A, B3, B4, B5, Y, X, B1 and B2 are as defined in any one of claims 1 to 10. Another subject of the invention is the compound as defined above for use as a medicament, in particular for preventing and/or treating inflammation and inflammatory diseases, immune and auto-immune diseases, pain related diseases, genetic diseases and/or cancer.

  本发明的一个主题是具有通式（I）的化合物，其药学上可接受的盐或其互变异构体，其中A、B3、B4、B5、Y、X、B1和B2如权利要求1至10中的任一所定义。本发明的另一个主题是上述定义的化合物作为药物的用途，特别用于预防和/或治疗炎症和炎症性疾病、免疫和自身免疫疾病、与疼痛有关的疾病、遗传疾病和/或癌症。
• Aryl-Diadamantyl Phosphine Ligands in Palladium-Catalyzed Cross-Coupling Reactions: Synthesis, Structural Analysis, and Application
  作者：Ádám Sinai、Dániel Cs. Simkó、Fruzsina Szabó、Attila Paczal、Tamás Gáti、Attila Bényei、Zoltán Novák、András Kotschy

  DOI：10.1002/ejoc.201901834

  日期：2020.3.8

  Bulky diadamantyl aryl phoshine ligands were synthesized and utilized in Buchwald‐Hartwig coupling reactions of sterically demanding ortho‐substituted aryl chlorides. The ligands also showed enhanced catalytic activity in the coupling of tosyl hydrazones and aryl halides.

  合成了大体积的二金刚烷基芳基膦配体，并将其用于空间要求的邻位取代的芳基氯化物的Buchwald-Hartwig偶联反应中。在甲苯磺酰also和芳基卤化物的偶联中，配体还显示出增强的催化活性。
• [EN] NOVEL COMPOUNDS FOR THE DIAGNOSIS, TREATMENT AND PREVENTION OF DISEASES ASSOCIATED WITH THE AGGREGATION OF ALPHA-SYNUCLEIN<br/>[FR] NOUVEAUX COMPOSÉS POUR LE DIAGNOSTIC, LE TRAITEMENT ET LA PRÉVENTION DE MALADIES ASSOCIÉES À L'AGRÉGATION DE L'ALPHA-SYNUCLÉINE
  申请人：MODAG GMBH

  公开号：WO2021099518A1

  公开（公告）日：2021-05-27

  The present invention relates to compounds represented by general formula (la), (lb), (lla) or(llb). These compounds are suitable for imaging alpha-synuclein and for diagnosing diseases which are associated with the aggregation of alpha-synuclein. The compounds are also useful for treating and preventing diseases which are associated with the aggregation of alpha-synuclein.

  本发明涉及由通式(la)、(lb)、(lla)或(llb)表示的化合物。这些化合物适用于成像α-突触核蛋白和诊断与α-突触核蛋白聚集相关的疾病。这些化合物还适用于治疗和预防与α-突触核蛋白聚集相关的疾病。
• [EN] HETEREOARYL NITRILE DERIVATIVES<br/>[FR] DERIVES D'HETEREOARYLE NITRILE
  申请人：NOVARTIS AG

  公开号：WO2004020441A1

  公开（公告）日：2004-03-11

  The invention provides compounds of Formula (I) or a pharmaceutically acceptable salt or ester thereof wherein the symbols have meaning as defined, which are inhibitors of cathepsin K and find use pharmaceutically for treatment of diseases and medical conditions in which cathepsin K is implicated, e.g. various disorders including inflammation, rheumatoid arthritis, osteoarthritis, osteoporosis and tumors.

  该发明提供了式（I）的化合物或其药用可接受的盐或酯，其中符号的含义如定义，这些化合物是卡特普辛K的抑制剂，并在药学上用于治疗卡特普辛K参与的疾病和医疗状况，例如各种疾病，包括炎症、类风湿关节炎、骨关节炎、骨质疏松症和肿瘤。

表征谱图